Author
Listed:
- Massimiliano Bissa
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Sohyoung Kim
(Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health)
- Veronica Galli
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Slim Fourati
(Case Western Reserve University
Emory University)
- Sarkis Sarkis
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Anush Arakelyan
(Section on Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health)
- Isabela Silva Castro
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Mohammad Arif Rahman
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Saori Fujiwara
(Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health)
- Monica Vaccari
(Animal Models and Retroviral Vaccines Section, National Cancer Institute
Tulane National Primate Research Center, Tulane University)
- Jeffrey A. Tomalka
(Case Western Reserve University
Emory University)
- James D. Stamos
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Luca Schifanella
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Giacomo Gorini
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Ramona Moles
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Anna Gutowska
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Guido Ferrari
(Duke University School of Medicine)
- Alexei Lobanov
(Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute)
- David C. Montefiori
(Duke University School of Medicine)
- George W. Nelson
(Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute)
- Margaret C. Cam
(Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute)
- Marita Chakhtoura
(Drexel University College of Medicine)
- Elias K. Haddad
(Drexel University College of Medicine)
- Melvin N. Doster
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
- Katherine McKinnon
(Vaccine Branch Flow Cytometry Core, National Cancer Institute)
- Sophia Brown
(Animal Models and Retroviral Vaccines Section, National Cancer Institute
Vaccine Branch Flow Cytometry Core, National Cancer Institute)
- David J. Venzon
(Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute)
- Hyoyoung Choo-Wosoba
(Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute)
- Matthew W. Breed
(Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory)
- Kristin E. Killoran
(Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory)
- Joshua Kramer
(Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory)
- Leonid Margolis
(Section on Intercellular Interactions, Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health)
- Rafick P. Sekaly
(Case Western Reserve University
Emory University)
- Gordon L. Hager
(Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health)
- Genoveffa Franchini
(Animal Models and Retroviral Vaccines Section, National Cancer Institute)
Abstract
The development of an effective vaccine to protect against HIV acquisition will be greatly bolstered by in-depth understanding of the innate and adaptive responses to vaccination. We report here that the efficacy of DNA/ALVAC/gp120/alum vaccines, based on V2-specific antibodies mediating apoptosis of infected cells (V2-ADCC), is complemented by efferocytosis, a cyclic AMP (cAMP)-dependent antiphlogistic engulfment of apoptotic cells by CD14+ monocytes. Central to vaccine efficacy is the engagement of the CCL2/CCR2 axis and tolerogenic dendritic cells producing IL-10 (DC-10). Epigenetic reprogramming in CD14+ cells of the cyclic AMP/CREB pathway and increased systemic levels of miRNA-139-5p, a negative regulator of expression of the cAMP-specific phosphodiesterase PDE4D, correlated with vaccine efficacy. These data posit that efferocytosis, through the prompt and effective removal of apoptotic infected cells, contributes to vaccine efficacy by decreasing inflammation and maintaining tissue homeostasis.
Suggested Citation
Massimiliano Bissa & Sohyoung Kim & Veronica Galli & Slim Fourati & Sarkis Sarkis & Anush Arakelyan & Isabela Silva Castro & Mohammad Arif Rahman & Saori Fujiwara & Monica Vaccari & Jeffrey A. Tomalka, 2023.
"HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC,"
Nature Communications, Nature, vol. 14(1), pages 1-19, December.
Handle:
RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36109-8
DOI: 10.1038/s41467-023-36109-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36109-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.